Indocyanine Green for Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumor, Neoplasms

In brief

According to the World Health Organization, cancer is a leading cause of death in men and women, accounting for 7.6 million deaths (around 13% of all deaths) in 2008. Surgery remains the best option for patients presenting with operable Stage I or II cancers, however the five year survival rate for these candidates remains at a dismally low. The high rates of recurrence suggest that surgeons are unable to completely detect and remove primary tumor nodules in a satisfactory manner as well as lingering metastases in sentinel lymph nodes. By ensuring a negative margin through near-infrared imagery it would be possible for us to improve the rates of recurrence from patients and thus overall survival.

Key facts

Study ID

NCT02280954

Run by

University of Pennsylvania

People needed

48

Starts

2013-11-01

Expected to finish

2017-02-01

Last updated by the study team

2018-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients over 18 years of age
• Patients presenting with a solid tumor presumed to be resectable cancer and are at risk for local recurrence on pre-operative assessment
• Good operative candidate as determined by the treating physician and multidisciplinary team
• Subject capable of giving informed consent and participating in the process of consent.

You may not qualify if…

• Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery
• Subjects with a history of iodide allergies
• Vulnerable patient populations
• People who would be easily lost to follow up
• Patients unable to participate in the consent process (children and neonates).

Where it is running

• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.